Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

Jacob D. SoumeraiCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA

Matthew D. HellmannCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA

Yang FengDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA

Aliyah R. SohaniHarvard Medical School, Boston, MA, USA;Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

Christiana E. ToomeyCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Jeffrey A. BarnesCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA

Ronald W. TakvorianCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA

Donna NeubergDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA

Ephraim P. HochbergCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA

Jeremy S. AbramsonCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USACorrespondence[email protected]

show all

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

Supplementary Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

Supplementary Material

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date